文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌患者的姑息治疗使用情况

Palliative care use amongst patients with bladder cancer.
PubMed 文献 · BJU Int · 2019-03-12

基于监测、流行病学和最终结果-医疗保险数据,纳入2008至2013年诊断的7303例肌层浸润性膀胱癌患者,262例(3.6%)接受了姑息治疗。多变量分析显示接受姑息治疗者更可能较年轻、女性、合并症更多、居住在美国中部以及接受根治性膀胱切除术而非保留膀胱方案。调整后接受姑息治疗的概率随时间无显著变化。

要点

  • 7303例肌层浸润性膀胱癌中262例(3.6%)接受姑息治疗。
  • 2185例晚期膀胱癌中90例(4.1%)接受姑息治疗。
  • 接受姑息治疗者多数(>80%,>210/262)在诊断后24个月内使用。

核心结论

  • 尽管有强证据支持将姑息治疗纳入标准肿瘤治疗,但膀胱癌患者中姑息治疗使用率低至4%。
  • 本研究提供了当前姑息治疗使用的保守基线估计,应作为进一步调查医生、患者和系统层面障碍的基础。

研究设计与样本

  • 利用监测、流行病学和最终结果-医疗保险数据,识别2008至2013年间诊断的肌层浸润性膀胱癌患者。
  • 主要结局为接受姑息治疗,定义为由临终关怀与姑息医学专科医生提交的索赔记录。
  • 使用逻辑回归分析检验姑息治疗使用的决定因素。

主要发现

  • 研究期间共7303例患者诊断为肌层浸润性膀胱癌,262例(3.6%)接受了姑息治疗。
  • 2185例晚期膀胱癌(定义为T4、N+或M+疾病)中,90例(4.1%)接受了姑息治疗。
  • 接受姑息治疗的患者中多数(>80%,>210/262)在诊断后24个月内接受该治疗。
  • 多变量分析显示,接受姑息治疗的患者更可能较年轻、女性、合并症更多、居住在美国中部,以及接受根治性膀胱切除术而非保留膀胱方案。
  • 调整后接受姑息治疗的概率随时间无显著变化。

局限性

  • 本研究提供了当前姑息治疗使用的保守基线估计,应作为进一步调查医生、患者和系统层面障碍的基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the rate and determinants of palliative care use amongst Medicare beneficiaries with bladder cancer and encourage a national dialogue on improving coordinated urological, oncological, and palliative care in patients with genitourinary malignancies. PATIENTS AND METHODS: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified patients diagnosed with muscle-invasive bladder cancer (MIBC) between 2008 and 2013. Our primary outcome was receipt of palliative care, defined as the presence of a claim submitted by a Hospice and Palliative Medicine subspecialist. We examined determinants of palliative care use using logistic regression analysis. RESULTS: Over the study period, 7303 patients were diagnosed with MIBC and 262 (3.6%) received palliative care. Of 2185 patients with advanced bladder cancer, defined as either T4, N+ , or M+ disease, 90 (4.1%) received palliative care. Most patients that received palliative care (>80%, >210/262) did so within 24 months of diagnosis. On multivariable analysis, patients receiving palliative care were more likely to be younger, female, have greater comorbidity, live in the central USA, and have undergone radical cystectomy as opposed to a bladder-sparing approach. The adjusted probability of receiving palliative care did not significantly change over time. CONCLUSIONS: Palliative care provides a host of benefits for patients with cancer, including improved spirituality, decrease in disease-specific symptoms, and better functional status. However, despite strong evidence for incorporating palliative care into standard oncological care, use in patients with bladder cancer is low at 4%. This study provides a conservative baseline estimate of current palliative care use and should serve as a foundation to further investigate physician-, patient-, and system-level barriers to this care.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hugar LA, Lopa SH, Yabes JG, et al. Palliative care use amongst patients with bladder cancer. BJU Int. 2019. PMID: 30758125. doi:10.1111/bju.14708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。